1,147 results on '"Schiff, Eugene"'
Search Results
2. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
4. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
5. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
6. Deferred treatment with sofosbuvir–velpatasvir–voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1
7. Barriers to Hepatitis C Screening in a Minority Population : A Comparison of Hepatitis C and Human Immunodeficiency Virus Screening Rates at a Community STD Clinic in Miami, Florida
8. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial
9. Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease
10. Hispanics With Primary Biliary Cirrhosis Are More Likely to Have Features of Autoimmune Hepatitis and Reduced Response to Ursodeoxycholic Acid Than Non-Hispanics
11. Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study
12. Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population
13. Drug-Induced Cholestasis
14. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B
15. Vascular Diseases, Abscesses, and Cysts
16. Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States
17. Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B
18. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid
19. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence
20. Reply
21. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
22. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
23. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy
24. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution
25. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease
26. An Update on the Hepatitis E Virus
27. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
28. Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV
29. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance
30. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update
31. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma
32. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
33. Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
34. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
35. Peginterferon Alfa-2b orAlfa-2a with ribavirin for treatment of hepatitis C infection
36. Imatinib Mesylate (Gleevec) Hepatotoxicity
37. Predictors of Cirrhosis in Hispanic Patients with Nonalcoholic Steatohepatitis
38. Early Detection of Steatohepatitis: Less Teeth NASHing and More Research?
39. CASE REPORT: Beneficial Effects of Topical Testosterone Replacement in Patients with End-Stage Liver Disease
40. Multicenter, Double‐Blind, Randomized Trial of Emricasan in Hepatitis C–Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis
41. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinoma-A phase II trial
42. Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
43. Part Introduction
44. Hepatitis C and alcohol
45. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. (Major Article)
46. Hepatitis B Virus Reactivation After Cytotoxic Chemotherapy: The Disease and Its Prevention
47. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
48. Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy
49. Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay
50. Characteristics of the Interferon-Ineligible and Interferon-Intolerant Hepatitis C Patients Enrolled in a Large Phase 2 Clinical Study: 784
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.